Midatech Pharma plc (NASDAQ:MTP – Get Rating)’s stock is set to reverse split before the market opens on Monday, March 27th. The 1-4 reverse split was announced on Monday, March 27th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, March 27th.
Midatech Pharma Trading Up 6.1 %
NASDAQ MTP opened at $0.36 on Friday. Midatech Pharma has a twelve month low of $0.33 and a twelve month high of $5.25. The firm’s 50 day moving average price is $0.60 and its two-hundred day moving average price is $1.44.
Hedge Funds Weigh In On Midatech Pharma
A hedge fund recently bought a new stake in Midatech Pharma stock. Armistice Capital LLC purchased a new stake in shares of Midatech Pharma plc (NASDAQ:MTP – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 386,828 shares of the company’s stock, valued at approximately $381,000. Armistice Capital LLC owned approximately 1.79% of Midatech Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 4.21% of the company’s stock.
About Midatech Pharma
Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm’s proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale.
- Get a free copy of the StockNews.com research report on Midatech Pharma (MTP)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.